Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Uterine Artery Embolization(UAE) Versus High-Intensity-Focused-Ultrasound(HIFU) for Treatment of Uterine Fibroids

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01834703
Recruitment Status : Terminated
First Posted : April 18, 2013
Last Update Posted : August 30, 2019
Sponsor:
Collaborator:
Prince of Wales Hospital, Shatin, Hong Kong
Information provided by (Responsible Party):
Simon Yu, Chinese University of Hong Kong

Brief Summary:
This study aimed to evaluate the clinical effectiveness and adverse effects of Uterine Artery Embolization (UAE), High-Intensity-Focused-Ultrasound (HIFU) in treating patients with uterine fibroid.

Condition or disease Intervention/treatment Phase
Uterine Fibroids Procedure: UAE Procedure: HIFU Not Applicable

Detailed Description:
The usual management for symptomatic uterine fibroid is surgery (myomectomy or hysterectomy), in the current study, uterine artery embolization (UAE) is a form of non-surgical and minimally invasive treatment, High-Intensity-Focused-Ultrasound (HIFU) is a form of non-invasive treatment that can be completed as an out-patient within hours. Embolization causes ischaemia and shrinkage of the fibroid and therefore symptomatic relieve. HIFU is a medical technology that has been used for cancer treatment. Energy is delivered from outside the body in a non-invasive manner to produce heat energy that causes necrosis and shrinkage of the uterine fibroid thereby relieves the symptoms due to the fibroid. It does not involve radiation. The clinical effectiveness of HIFU for uterine fibroid is unknown, however, based on the knowledge of the clinical effectiveness of HIFU on liver cancer and pancreatic cancer, there is reasonable ground to believe that HIFU is effective for uterine fibroid.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 85 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Controlled Trial of Uterine Artery Embolization (UAE) Versus High-Intensity-Focused-Ultrasound (HIFU) for Treatment of Patients With Uterine Fibroids
Study Start Date : May 2009
Actual Primary Completion Date : December 2015
Actual Study Completion Date : December 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ultrasound

Arm Intervention/treatment
Active Comparator: UAE treatment
After randomization, patient recruited will be arranged to receive UAE treatment. 100 patients will be recruited for UAE treatment
Procedure: UAE
The patient will be admitted into hospital for UAE. UAE was performed with patients under local anesthesia. Embosphere particles (BioSphere Medical) with a size of 500 - 700µm were used in all procedures. Embospheres were mixed with contrast material and saline and injected into each uterine artery until either parenchyma filling of the fibroids had stopped (target embolization) or the main uterine artery was blocked with stasis of contrast material (selective embolization). After the procedure, women were admitted to the gynecology ward for postprocedural care. All patients were advised to stay in the hospital for at least 1 night.

Active Comparator: HIFU
After randomization, patient recruited will be arranged to receive HIFU treatment. 100 patients will be recruited for HIFU treatment
Procedure: HIFU
Treatment will be given to the patient in one or more sessions on an outpatient basis. The uterine fibroid will be identified and located with ultrasonography and ablated with HIFU. For lesion beyond 6 cm distance from skin, HIFU is given at a power of 1200-1500 watt for 1500 - 2000 times at each spot, for 50 milli-second each time, at an interval of 100 milli-second, at a spot distance of 1.5cm, a line distance of 1.5cm, and a plane distance of 1.0 -1.5cm; for lesion within 6 cm distance from skin, HIFU is given at a power of 1300±15% Watt for 40 times at each spot, for120 milli-second each time, at an interval of 100 milli-second, at a spot distance of 0.3cm, a line distance of 0.3cm, and a plane distance of 0.8cm.




Primary Outcome Measures :
  1. Treatment success rate [ Time Frame: 6 months ]
    Technical success of treatment procedure and absence of symptoms of fibroid


Secondary Outcome Measures :
  1. Incidence of procedure related complication [ Time Frame: 1, 3, 6, 12 months after treatment ]
    Complications after treatment procedures will be recorded during each hospital admission and during each HIFU treatment session. Major adverse events will be reported. Complications that occur prior to a clinical visit will be documented and graded in each clinical visit at 1, 3, 6 and 12 month after treatment.

  2. volume change of the fibroids [ Time Frame: 6, 12 months after treatment ]
    Assessed by 3 Dimensional ultrasonography (USG)

  3. Degree of infarction of the fibroids [ Time Frame: 3, 15 months after treatment ]
    Contrast enhanced magnetic resonance imaging (MRI) is used to assess the degree of infarction, which is defined as non-perfused tissue on contrast MRI.

  4. Vascularity of the fibroids [ Time Frame: 6, 12 months after treatment ]
    Assessed by contrast enhanced USG. Vascularity of the fibroid will be classified into six categories: 0%, <25%, 25 to 50%, >50 to 75%, >75%, 100%.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 47 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female gender
  • Age between 30 and 47
  • Pre or peri menopausal with Follicle-stimulating hormone (FSH) less than 40 mIU/ml
  • Weight less than 140kg (or 310lbs) and Body Mass Index (BMI) less than 33
  • Cervical cytology no more severe than low grade SIL
  • Negative urine pregnancy test
  • Uterine size less than 24 weeks based on physical exam assessment
  • History of uterine leiomyoma causing symptoms of bleeding, pressure, or pain. Excessive uterine bleeding will be evidenced by either one of the following-profuse bleeding with flooding or clots or repetitive periods lasting for more than 8 days; or anemia due to acute or chronic blood loss OR pelvic discomfort caused by leiomyomata, either acute and severe or chronic lower abdominal or low back pressure or bladder pressure with urinary frequency not due to urinary tract infection
  • Dominant intramural fibroid greater than or equal to 3 cm and less than or equal to 12 cm on imaging.
  • Good health other than history of leiomyomas. Chronic medications may be acceptable at the discretion of the research team.
  • No future fertility wish.
  • Are using abstinence, mechanical (condoms, diaphragms) or sterilization methods of contraception and are willing to continue using them throughout the study.
  • Willing and able to give informed consent.
  • Willing and able to comply with study requirements.
  • Normal menstrual cycle with endometrial pathology excluded
  • Normal renal function
  • Normal liver function
  • Platelet count greater than 50 K/microL
  • Normal coagulation profile

Exclusion Criteria:

  • Significant abnormalities in the history, physical or laboratory examination
  • History of or current thromboembolic event (deep vein thrombosis, pulmonary embolus, stroke)
  • Other pelvic mass indicated by history or MR imaging such as endometriosis, ovarian tumor, acute or chronic pelvic inflammatory disease
  • Desire for future pregnancy
  • Pregnant or Positive pregnancy test
  • Lactation
  • Unexplained vaginal bleeding
  • Untreated severe cervical dysplasia
  • Intrauterine device
  • Need for interval use of narcotics
  • Extensive scarring along anterior lower abdominal wall (greater than 50% of area) or scar tissue or surgical clips in the direct path of the HIFU
  • Pedunculated submucosal or subserosal fibroid of size ≧5cm and with a stalk less than 25% of the maximal fibroid diameter.
  • Genetic causes of leiomyomata
  • Known recent rapid growth of fibroids, defined as a doubling in size in 6 months
  • Patient unwilling to receive non-surgical treatment
  • Contraindication to MRI due to severe claustrophobia or implanted metallic device.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01834703


Locations
Layout table for location information
Hong Kong
Department of Imaging and Interventional Radiology, Prince of Wales Hospital, The Chinese University of Hong Kong
Hong Kong, Hong Kong
Department of Obstectrics and Gynaecology, Prince of Wales Hospital
Hong Kong, Hong Kong
Sponsors and Collaborators
Chinese University of Hong Kong
Prince of Wales Hospital, Shatin, Hong Kong
Investigators
Layout table for investigator information
Principal Investigator: Simon CH Yu, MD, FRCR Chinese University of Hong Kong
Layout table for additonal information
Responsible Party: Simon Yu, Professor, Chinese University of Hong Kong
ClinicalTrials.gov Identifier: NCT01834703    
Other Study ID Numbers: VIR-13-02
First Posted: April 18, 2013    Key Record Dates
Last Update Posted: August 30, 2019
Last Verified: February 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Leiomyoma
Myofibroma
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Connective Tissue
Connective Tissue Diseases